Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial

Lei Xu,Liyin Li,Qiutang Wang,Bing Pan,Leilei Zheng,Zheng Lin

DOI: https://doi.org/10.1016/j.jad.2024.05.063

IF: 6.533

2024-05-18

Journal of Affective Disorders

Abstract:Background Pharmacotherapy is one of the primary treatment modalities for depression. However, there is considerable variability in the individual response to antidepressant medications. Personalized medicine guided by pharmacogenomic testing may hold promise in addressing this issue. Methods In this study, 665 depressive patients were randomly enrolled into two groups: the pharmacogenomic testing group ( n = 333) and the control group ( n = 332). In the testing group, participants underwent pharmacogenomic testing, and clinicians customized the treatment plan with the result, while the control group relied solely on clinicians' experience. The primary outcomes were the proportion of remission and response, assessed with Hamilton Depression Rating Scale (HDRS). The secondary outcomes included changes in HDRS scores over time and frequency of adverse drug reactions by the participants. Results At week 8, the pharmacogenomic testing group showed significantly higher remission rates (24.0 % v.s. 15.1 %; RR = 1.117; P = 0.007) and response rates (39.3 % v.s. 25.7 %; RR = 1.225; P < 0.001) compared to the control group. By week 12, the pharmacogenomic testing group continued to demonstrate significant advantages in remission (31.0 % v.s. 20.0 %; RR = 1.159; P = 0.003) and response (48.7 % v.s. 37.3 %; RR = 1.224; P = 0.006). Additionally, adverse drug reactions were less frequent in the pharmacogenomic testing group. Limitations This study is not blind to clinicians and it's a single-center study. Conclusions: Pharmacogenomic testing-guided drug therapy can provide greater assistance in the treatment of depression.

psychiatry,clinical neurology